Clinical development plan: l-perillyl alcohol.
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006224:Cricetinae; D017277:Drug Approval; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D039821:Monoterpenes; D009374:Neoplasms, Experimental / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D051381:Rats; D012107:Research Design; D013729:Terpenes / Q000494:pharmacology / Q000627:therapeutic use*; D018675:Toxicity Tests
D016588:Anticarcinogenic Agents; D039821:Monoterpenes; D013729:Terpenes; C032208:perillyl alcohol